Laboratory Workup for Post-Mononucleosis Chronic Fatigue in a 21-Year-Old
Order a complete blood count with differential, comprehensive metabolic panel including liver enzymes, ACTH level, and EBV-specific antibody testing (VCA-IgG, EA-IgG, EBNA) to evaluate for chronic active EBV infection and post-infectious fatigue syndrome.
Initial Standard Laboratory Tests
Start with routine clinical labs that have demonstrated predictive value for post-infectious chronic fatigue syndrome (PI-CFS):
- Complete blood count with differential: Look for persistent lymphocytosis (>50% lymphocytes) or atypical lymphocytes (>10%), and monitor neutrophil count which can show significant departure from normal at 24 months in PI-CFS 1
- Comprehensive metabolic panel with liver enzymes: Elevated transaminases support ongoing EBV activity and increase clinical suspicion even with negative heterophile antibodies 2
- ACTH level: Lower ACTH at 6 months post-IM is highly predictive of developing CFS (p=0.02), with levels potentially showing deficiency again at 24 months 1
EBV-Specific Virological Testing
Given the concern for chronic active EBV infection (CAEBV) versus simple post-infectious fatigue, obtain:
- EBV antibody panel: Measure VCA-IgG and EA-IgG titers. CAEBV typically shows VCA-IgG ≥1:640 and EA-IgG ≥1:160 3
- Quantitative EBV DNA PCR: More than 10^2.5 copies/mg DNA in peripheral blood mononuclear cells suggests CAEBV 3
Critical Distinction
The key clinical question is whether this represents benign post-infectious fatigue (which affects the majority and resolves within 3 months 4) versus CAEBV (which has poor prognosis and requires aggressive monitoring). CAEBV presents with persistent/intermittent fever, lymphadenopathy, hepatosplenomegaly, and systemic complications—not just isolated fatigue 3.
Additional Hormone Assessment
At 12 months post-infection, add estradiol levels, which show significant departure from normal specifically at this timepoint in PI-CFS patients (p=0.02) before recovering at 24 months 1. This sex hormone assessment combined with stress hormone (ACTH) monitoring provides temporal evolution patterns that differentiate PI-CFS from recovery.
Serial Monitoring Approach
The evidence demonstrates that biomarker expression evolves differently over time between PI-CFS and recovered patients 1. Therefore:
- Repeat CBC with differential and ACTH at 6-month intervals
- The 4% of IM patients who develop CFS show distinct temporal patterns in these routine markers
- Serial assessment is more valuable than single timepoint testing
Common Pitfalls to Avoid
- Don't rely on heterophile antibody testing at this stage: The monospot test is for acute diagnosis, not chronic evaluation 2
- Don't assume all post-IM fatigue is benign: While most fatigue resolves within 3 months 4, IM is a documented risk factor for chronic fatigue syndrome 4
- Don't miss CAEBV: This requires specific EBV antibody titers and quantitative PCR, not just clinical assessment. CAEBV can progress to T-cell or NK-cell lymphoproliferative disorders 3
When to Escalate Testing
If initial labs suggest CAEBV (high EBV titers, elevated EBV DNA, persistent cytopenias), consider referral for:
- Immunological studies including lymphocyte subset analysis and HLA-DR
- Cytokine analysis
- Evaluation for underlying lymphoproliferative disorder 3
The algorithmic approach prioritizes identifying the small subset (4%) who develop true PI-CFS 1 while ruling out the more serious CAEBV, which requires entirely different management and has significantly worse prognosis 3.